Category Specific RSS

News

VIP Gloves secure CE Mark approval for increased European distribution

Health and safety products manufacturer VIP Gloves (ASX: VIP) is readying for a significant increase in their manufacturing capacity with approval now secured from European regulators for their nitrile gloves, bringing with it increased margins on products sold.

The approval is widely recognised across the European Economic Area and signifies that VIP’s nitrile gloves conform with EU health and safety standards at a time when VIP Gloves has a 12 month production backlog due to heightened demand in response to the COVID-19 pandemic.

“Obtaining the CE Mark would allow VIP’s products to command higher selling prices while enabling us to expand our product distribution network directly to the European distributors as well as selling our products to existing distributors who service the European market,” said VIP Gloves Executive Director, Wee Min Chen.

Since the onset of COVID-19, VIP Gloves has continued to receive orders for their gloves which are manufactured in Malaysia, to the point where they are set to significantly expand their production capabilities.

With this demand, VIP has reported that they have increased the selling price of their gloves by 50% for the December quarter and are expecting to bring on their 7th and 8th production lines by April 2021.

For the quarter ending 30 September 2020, VIP Gloves reported $6.6m in sales revenue for a 37% increase in net cash flow to $1.4m for the quarter. The Company is expected to report their December quarter results this week.

Alfred Chan

Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.

Recent Posts

AML3D announces stronger FY26, with positive EBITDA reported in the second half

Adelaide-based metal printing group books record $12.5 million revenue and a record $78 million sales…

3 days ago

Refurbished tech gives Harris Technology a second life

Harris Technology has found a higher-margin growth engine in an unlikely place: the market for…

4 days ago

Imagion Biosystems Advances MagSense® Phase 2 Trial

Imagion Biosystems (ASX: IBX) is moving its MagSense® HER2 Imaging Agent Phase 1b/2 clinical trial…

1 week ago

Acrux-developed Menopause Hormone Therapy to enter Australian market

Acrux (ASX:ACR) is set to bring its transdermal Estradiol spray Lenzetto® to the Australian market…

3 months ago

Evion Expands Critical Minerals Push with Nevada Fluorspar Option

The race to secure Western-aligned critical minerals supply chains is accelerating as governments and industry…

4 months ago

Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone

Green360 Technologies (ASX:GT3) has taken a major step forward in the commercialisation of its low-carbon…

4 months ago